Myelofibrosis, Primary immune thrombocytopenia
KPTIKaryopharm TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for XPOVIO (Selinexor) in Myelofibrosis, Primary immune thrombocytopenia. The expected timing is based on the latest available company guidance and may change.
05/14/26:- SENTRY-2 60 mg cohort completed enrollment; top-line data expected H2 2026. 08/13/26:- SENTRY-2 40 mg cohort enrollment continues; 60 mg cohort topline data will be reported in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.